On Tuesday, the Food and Drug Administration (FDA) issued. And an emergency use authorization (EUA) for an updated iteration of the Novavax COVID-19 vaccine. This EUA, dated October 3rd, extends eligibility to individuals aged 12 and above, irrespective of their prior vaccination history. And as stated in a press release.
The FDA’s recent authorization was predicated on a combination of previously available safety and efficacy data. As well as insights gleaned from booster studies. It was not solely reliant on new clinical trial data specific to this particular vaccine formulation. This decision was articulated in an authorization letter dated October 3rd, signed by Peter Marks. And the Director of the FDA’s Center for Biologics Evaluation and Research.
This marks a departure from the earlier emergency use authorizations (EUAs) granted to Novavax vaccines, which were predominantly based on data from ongoing trials since the summer of the preceding year.
The previous version of the Novavax vaccine, authorized for individuals aged 18 and above in July 2022 and targeting the “Original monovalent” virus, saw its Food and Drug Administration (FDA) authorization relying on safety and efficacy data derived from an “ongoing phase 3 trial.” Subsequently, in the following month, the FDA extended authorization to individuals aged 12 to 17, hinging on data obtained from an expansion of the phase 3 trial aimed at adolescents.
In contrast, the latest iteration of the Novavax vaccine specifically tailored to combat the XBB.1.5 Omicron subvariant, a close relative to the strains currently in circulation. This development aligns with the approach taken by Pfizer and Moderna in updating their vaccines to address emerging variants.
Nevertheless, Novavax’s vaccine stands apart from Pfizer’s and Moderna’s in terms of its mechanism. Novavax employs a protein-based approach, which has been the traditional standard for vaccine development for many years. In contrast, Pfizer and Moderna harness mRNA technology in their vaccines.
In a statement, Dr. Marks highlighted the significance of this latest authorization. And emphasizing that it offers another COVID-19 vaccine choice that adheres to the FDA’s stringent criteria for safety, efficacy, and manufacturing quality required to support emergency use authorization.
An expert warns that “Disease X” has the potential to trigger the next pandemic.